Dose Selection for a Direct and Selective Factor IXa Inhibitor and its Complementary Reversal Agent: Translating Pharmacokinetic and Pharmacodynamic Properties of the REG1 System to Clinical Trial Design

Author: Povsic T.  

Publisher: Springer Publishing Company

ISSN: 0929-5305

Source: Journal of Thrombosis and Thrombolysis, Vol.32, Iss.1, 2011-07, pp. : 21-31

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content